BlackRock
IMUC

BlackRock’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

BlackRock’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-672
Closed – – 5206
2018
Q3 		$0 Hold
672
– – ﹤0.01% 5192
2018
Q2 		$0 Hold
672
– – ﹤0.01% 5201
2018
Q1 		$0 Hold
672
– – ﹤0.01% 5129
2017
Q4 		$0 Hold
672
– – ﹤0.01% 5126
2017
Q3 		$0 Hold
672
– – ﹤0.01% 5165
2017
Q2 		$1K Hold
672
– – ﹤0.01% 5010
2017
Q1 		$2K Buy
+672
New +$1.75K ﹤0.01% 4922

Other funds holding IMUC

WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

BlackRock's IMUC Position: Q4 2018 in Review

BlackRock sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 672 shares.

BlackRock first reported a position in IMUC in Q1 2017 and held it in 7 quarters. The position peaked at $2K in Q1 2017. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.

  • BlackRock reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
  • BlackRock sold 672 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018.
  • BlackRock first reported a position in ImmunoCellular Therapeutics, Ltd. in Q1 2017 and held it in 7 quarters.
  • BlackRock's ImmunoCellular Therapeutics, Ltd. position peaked at $2K in Q1 2017.
  • 3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.

Based on BlackRock's 13F filing for Q4 2018, filed 8 Feb 2019.